DiaMedica Therapeutics, Inc. $DMAC Shares Bought by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its holdings in DiaMedica Therapeutics by 76.7%, acquiring an additional 52,854 shares and bringing its total to 121,802 shares worth approximately $462,000.
• Analysts are generally optimistic about DiaMedica, with Lake Street Capital raising its price target to $14.00 and maintaining a "buy" rating, while MarketBeat reports a consensus "buy" rating with an average price target of $12.33.
• Insider activity has been notable, with major shareholder Jan Stahlberg acquiring 50,772 shares at $6.00 per share, increasing their position by 0.66% and signaling confidence in the company's future.

Goldman Sachs Group Inc. grew its holdings in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) by 76.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 121,802 shares of the company's stock after acquiring an additional 52,854 shares during the quarter. Goldman Sachs Group Inc. owned about 0.28% of DiaMedica Therapeutics worth $462,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Northern Trust Corp boosted its position in DiaMedica Therapeutics by 49.8% during the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after acquiring an additional 59,902 shares during the period. Royal Bank of Canada lifted its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after buying an additional 154,701 shares during the period. Jane Street Group LLC lifted its holdings in shares of DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock valued at $382,000 after buying an additional 58,457 shares during the period. Millennium Management LLC lifted its holdings in shares of DiaMedica Therapeutics by 151.8% in the fourth quarter. Millennium Management LLC now owns 84,829 shares of the company's stock valued at $461,000 after buying an additional 51,139 shares during the period. Finally, World Investment Advisors lifted its holdings in shares of DiaMedica Therapeutics by 17.0% in the first quarter. World Investment Advisors now owns 25,650 shares of the company's stock valued at $97,000 after buying an additional 3,735 shares during the period. Institutional investors and hedge funds own 10.12% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Lake Street Capital upped their price objective on DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a report on Friday, July 18th. Wall Street Zen lowered DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a report on Friday. Craig Hallum upped their price objective on DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a report on Friday, July 18th. Finally, HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, DiaMedica Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $12.33.

DiaMedica Therapeutics Stock Up 1.5%

Shares of NASDAQ DMAC opened at $6.94 on Friday. DiaMedica Therapeutics, Inc. has a 12 month low of $3.19 and a 12 month high of $7.49. The company has a market cap of $358.73 million, a price-to-earnings ratio of -10.06 and a beta of 1.40. The business has a fifty day simple moving average of $5.79 and a 200-day simple moving average of $4.64.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). As a group, sell-side analysts expect that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current fiscal year.

Insider Activity at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg bought 50,772 shares of DiaMedica Therapeutics stock in a transaction dated Wednesday, August 27th. The stock was acquired at an average cost of $6.00 per share, with a total value of $304,632.00. Following the completion of the acquisition, the insider directly owned 7,764,465 shares in the company, valued at approximately $46,586,790. This trade represents a 0.66% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 2,542,857 shares of company stock worth $11,358,598 over the last three months. Corporate insiders own 7.30% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.